Tumorad® Takes a Major Leap Forward as Spago Nanomedical Forms Scientific Advisory Board

Today, Spago Nanomedical AB (publ) is pleased to announce the formation of its Scientific Advisory Board (SAB), a highly esteemed group of oncology and nuclear medicine experts who will provide invaluable guidance to the clinical development of their radiopharmaceutical program Tumorad and the 177Lu-SN201 candidate drug.

The esteemed members of the SAB are Professor Sten Nilsson, Professor Kristian Pietras, and Dr. Austin Smith. By enlisting the expertise of these clinical and scientific experts, Spago Nanomedical is taking a key step forward in their pursuit of the greatest possible outcomes for their research.

We are delighted to announce the expansion of Spago Nanomedical’s Scientific Advisory Board for Tumorad with the addition of Austin, Kristian and Sten. They bring to the board a remarkable collection of knowledge and experience in the creation of revolutionary therapies for cancer through radionucleotide application.

Their skills will be invaluable as we take Tumorad through the clinical and regulatory phases, which just recently kicked off through the submission of a phase I/IIa clinical trial application for patients with advanced cancer. CEO Mats Hansen looks forward to the new board members guiding Spago Nanomedical through this undeniable milestone.

The expert SAB will play a pivotal part in guiding the progress of Tumorad’s clinical development initiatives. By vigilantly monitoring existing data and providing their scientific and medical insight, the Advisory Board will help ensure that Tumorad’s goals of delivering a new therapeutic option to qualified individuals are met. To ensure that the program keeps achieving its objectives, additional members may be included in the Board as the project progresses.

Professor Sten Nilsson

Sten is a renowned professor emeritus in oncology and nuclear medicine from Karolinska – where he was responsible for the groundbreaking study design and early clinical program Xofigo™ (formerly Alpharadin™). As if this wasn’t enough, Sten was also the former chairman of the Swedish Oncology Association (SOF) and the Swedish Association for Nuclear Medicine (SFNM), as well as a member of the European Association for Nuclear Medicine’s Radionuclide Therapy Task Force. With a prolific writing career that boasts over 200 scientific articles, Sten is an invaluable figure in the medical field.

Professor Kristian Pietras

Kristian is a renowned professor of Molecular Medicine at Lund University, specializing in the connection between basic science, clinical science and the pharmaceutical industry when it comes to translational cancer research. His groundbreaking discoveries show that tumors are actually composed of multiple interacting cell types that are responsible for sustaining the progression of cancer. Not only is Kristian an elected member of the Royal Physiographic Society, he is also a member and chairman of the prestigious Young Academy of Sweden. His achievements also include the publication of more than 100 research articles and patents.

Dr. Austin Smith

Austin is a highly qualified Medical Oncologist and Pharmaceutical Medicine specialist, graduating from the Royal College of Surgeons in Ireland. His extensive experience in Oncology and Malignant Hematology, as well as Regulatory Science, has seen him ascend to executive positions in biopharma companies around Europe, the US and Asia-Pacific.

Austin is also a respected member of the Expert Group for Oncology, representing the Faculty of Pharmaceutical Medicine in the UK. His distinguished career demonstrates his expertise and dedication to improving the diagnosis, treatment and cure of cancers.

Spago Nanomedical AB, a Swedish nanomedicines company with a revolutionary platform of polymeric materials – enabling more precise diagnosis and treatment of life-threatening and debilitating diseases – is now moving from clinical trials to clinical development. The company’s share is listed on the Nasdaq First North Growth Market (ticker: SPAGO), allowing everyone to get involved in this potential game changer in the healthcare industry!

Leave a Comment